Early Results of Dexamethasone Implant, Ranibizumab, and Triamcinolone in Macular Edema Due to Branch Retinal Vein Occlusion

Yumuşak, Erhan; Büyüktortop, Nesrin; Örnek, Kemal

doi:10.5301/ejo.5000637

Cited by 14 publications

(14 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intravitreal corticosteroids is another option, particularly in situations where the cost of treatment and the monthly treatment burden of anti-VEGF therapy is too difficult for patients [124]. The most commonly used steroid drug is triamcinolone acetonide (TA), which is reported to have similar or even better short-term outcomes especially in nonischemic BRVO compared with anti-anti-VEGF drugs.…”

Section: Treatmentmentioning

confidence: 99%

“…Research has demonstrated that both 3-month intravitreal injections of an anti-VEGF agent bevacizumab and two IVTA injections 2 months apart could be effective in respect to both visual and anatomical outcomes [125]. TA has much lower prices but has a higher rate of adverse events like increased intraocular pressure (IOP), cataract progression, and sterile pseudoendophthalmitis [101, 124, 126–130]. The SCORE study ( n = 411) showed that the outcome of IVTA 1 mg groups is similar to IVTA 4 mg groups and can lower the rate of adverse events [131].…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion

Paulus

Shuai

et al. 2017

Journal of Ophthalmology

View full text Add to dashboard Cite

For years, branch retinal vein occlusion is still a controversial disease in many aspects. An increasing amount of data is available regarding classification, pathogenesis, risk factors, natural history, and therapy of branch retinal vein occlusion. Some of the conclusions may even change our impression of branch retinal vein occlusion. It will be beneficial for our doctors to get a deeper understanding of this disease and improve the treatment skills. The aims of this review is to collect the information above and report new ideas especially from the past a few years.

show abstract

Section: Treatmentmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion

Paulus

Shuai

et al. 2017

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Both inflammation and increased vascular endothelial growth factor (VEGF) level play important role in pathogenesis of ME secondary to RVO (4)(5)(6)(7). Laser photocoagulation, vitreoretinal surgery, intravitreal anti-VEGF and steroid injections, and various surgical techniques have been reported to be effective in treatment of ME secondary to RVO (1)(2)(3)(4)(5)(6)(7)(8).Currently, intravitreal injections are particularly preferred as first-line treatment option for ME (8). Bevacizumab, ranibizumab, and aflibercept are the 3 anti-VEGF agents used in treatment.…”

Section: Introductionmentioning

confidence: 99%

“…Bevacizumab, ranibizumab, and aflibercept are the 3 anti-VEGF agents used in treatment. The first drug is used off-label; the others are approved for this purpose (2,8,(9)(10)(11)(12). In pivotal multicenter studies in which strict follow-up and treatment criteria were observed, successful treatment outcomes have been reported (9)(10)(11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

Ranibizumab versus Aflibercept in Macular Edema Secondary to Retinal Vein Occlusion in Real Life: A Retrospective Case Control Study

Özkaya¹

2017

Beyoglu Eye J

View full text Add to dashboard Cite

Objectives:The present study is comparison of efficacy of ranibizumab and aflibercept in the treatment of macular edema (ME) secondary to retinal vein occlusion (RVO) in real life. Methods: Design was retrospective, case-control study. Treatment naïve RVO patients with ME who were treated with ranibizumab or aflibercept and had minimum follow-up time of 6 months were included. Primary outcome measures were changes in best corrected visual acuity (BCVA) and central retinal thickness (CRT). Secondary outcome measure was number of injections administered. Results: Mean baseline, month 3, and month 6 BCVA in ranibizumab group was 0.95±0.61-, 0.50±0.30-, and 0.66±0.58 logarithm of the minimum angle of resolution (LogMAR), respectively. Mean baseline, month 3, and month 6 BCVA in aflibercept group was 0.85±0.65-, 0.61±0.58-, and 0.65±0.55 LogMAR, respectively. Mean baseline, month 3, and month 6 CRT in ranibizumab group was 598±189-, 473±162-, and 359±134 μm, respectively. Mean baseline, month 3, and month 6 CRT in aflibercept group was 512±141-, 345±154-, and 374±172 μm, respectively. Mean number of injections was 2.7±0.8 for ranibizumab group, and 2.2±1.0 for aflibercept group (p=0.08). Conclusion: Ranibizumab and aflibercept are both effective agents in the treatment of ME secondary to RVO. Visit and injection figures were lower than those reported in prospective, multicenter studies, as expected, but functional and anatomical outcomes were comparable.

show abstract

“…Inflammation and increased vascular endothelial growth factor (VEGF) levels both play important role in pathogenesis of ME secondary to RVO (4)(5)(6)(7). Several treatment options such as laser photocoagulation, vitreoretinal surgery, intravitreal anti-VEGF and steroid injections, as well as various surgical techniques have been reported to be effective in treatment of ME secondary to RVO (1)(2)(3)(4)(5)(6)(7)(8). Currently, intravitreal injections of anti-VEGF agents or steroids are preferred as first line treatment option for ME (8).…”

Section: Introductionmentioning

confidence: 99%

Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion in a Real Life Practice: A Retrospective Case Series

Özkaya¹

2016

Beyoglu Eye J

View full text Add to dashboard Cite

The present study evaluated treatment outcomes of intravitreal ranibizumab (IVR) use in patients with macular edema (ME) secondary to retinal vein occlusion (RVO), and mean number of visits and injections of first year of treatment. Methods: The study was a retrospective case series. Newly diagnosed RVO patients who had macular edema for <3 months at first admission, were treatment naïve for ME, and had follow-up of at least 12 months were included. Some patients received initial loading dose of 3 consecutive monthly injections. There were no strict criteria for administering loading dose. Patients were followed monthly, and single injection of IVR was repeated when visual acuity decreased by 1 or more lines on Early Treatment Diabetic Retinopathy Study chart compared to most recent visit, or any increase in central retinal thickness (CRT) in optical coherence tomography images was observed. Primary outcome measures of this study included change in best corrected visual acuity (BCVA) and CRT. Secondary outcome measures were number of visits and number of injections administered. Results: Mean BCVA at baseline and months 3, 6, 9, and 12 was 0.27±0.27 decimals (range: 0.1-0.8), 0.42±0.28 decimals (range: 0.1-1.0), 0.39±0.26 decimals, (range: 0.01-0.8), 0.37±0.29 decimals (range: 0.01-0.9), and 0.42±0.30 decimals (range: 0.01-0.9), respectively. Mean BCVA was statistically better than mean baseline BCVA at all time points except month 9 (p=0.06 for month 9, and p<0.05 for month 3, 6, and 12). Mean CRT at baseline, months 3, 6, 9, and 12 was 581±188 microns (range: 300-894), 439±152 microns (range: 246-874), 383±149 microns, (range: 221-830), 425±238 microns (range: 235-1147), and 359±101 microns (range: 229-655), respectively. Mean CRT level was statistically lower than mean baseline BCVA (p<0.05 for all) at all time points. At month 12, 17 of the 45 patients (37.8%) had anatomically inactive ME and did not require injections. Mean number of planned visits at month 12 was 4.8±1.0 (range: 2-7), and number of completed visits was 4.5±1.2 (range: 1-6) (94.2% completion). Mean number of planned injections at month 12 was 3.8±1.5 (range: 1-8), and number of injections performed was 3.5±1.4 (range: 1-7) (92.0% completion). Conclusion: Ranibizumab is an effective agent in treatment of ME secondary to RVO with regard to visual and anatomical outcomes. Number of visits and injections were lower than prospective multicenter studies, as expected, yet functional and anatomical outcomes were acceptable.

show abstract

Early Results of Dexamethasone Implant, Ranibizumab, and Triamcinolone in Macular Edema Due to Branch Retinal Vein Occlusion

Abstract: Although RAN was the safest among the 3 agents, DEX and IVTA reduced CMT more than RAN, while significant improvement was achieved in BCVA in all groups. All 3 agents can be effectively used in the treatment of macular edema due to BRVO.

Cited by 14 publications

References 36 publications

New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion

New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion

Ranibizumab versus Aflibercept in Macular Edema Secondary to Retinal Vein Occlusion in Real Life: A Retrospective Case Control Study

Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion in a Real Life Practice: A Retrospective Case Series

Contact Info

Product

Resources

About